MicroRNAs: Novel Regulators Involved in the Pathogenesis of Psoriasis?
2007

MicroRNAs and Psoriasis: Understanding the Role of miR-203

Sample size: 25 publication Evidence: moderate

Author Information

Author(s): Sonkoly Enikö, Wei Tianling, Janson Peter C.J., Sääf Annika, Lundeberg Lena, Tengvall-Linder Maria, Norstedt Gunnar, Alenius Harri, Homey Bernhard, Scheynius Annika, Ståhle Mona, Pivarcsi Andor

Primary Institution: Karolinska Institutet, Stockholm, Sweden

Hypothesis

Psoriasis-affected skin has a specific microRNA expression profile compared to healthy skin and atopic eczema.

Conclusion

The study reveals that microRNA deregulation, particularly of miR-203, is involved in the pathogenesis of psoriasis.

Supporting Evidence

  • Psoriasis skin shows a specific microRNA expression profile compared to healthy skin.
  • miR-203 is exclusively expressed by keratinocytes and is up-regulated in psoriatic plaques.
  • The down-regulation of SOCS-3 in psoriatic skin is linked to the up-regulation of miR-203.
  • miR-146a is also significantly over-expressed in psoriatic skin compared to healthy skin.
  • miR-203's expression is more than 100-fold higher in skin compared to other organs.
  • Altered microRNA expression may contribute to the dysfunction of cell communication in psoriasis.
  • miRNAs represent potential therapeutic targets for chronic skin inflammation.

Takeaway

This study found that a special type of tiny molecules called microRNAs are different in the skin of people with psoriasis, which might help explain why they have this skin condition.

Methodology

The study analyzed microRNA expression in skin samples from psoriasis patients, healthy individuals, and atopic eczema patients using microarray and quantitative real-time PCR.

Potential Biases

Potential bias in patient selection and the influence of environmental factors on microRNA expression.

Limitations

The study's sample size is relatively small and focused on specific populations.

Participant Demographics

Caucasian individuals aged 18-65, including patients with moderate to severe chronic plaque psoriasis and healthy controls.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pone.0000610

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication